Notal Vision
Amit Pascal is an experienced engineering professional currently serving as the Director of System Engineering & Product Development at Notal Vision since April 2016, focusing on the development of innovative medical devices, overseeing system architecture, project timelines, budgets, and clinical trials. Previously, Amit held the position of Principal Electro Optics Engineer at Medtronics (Given Imaging) from January 2005 to March 2016, leading the electro optical group and future technology initiatives. Earlier roles include Head of the Electro Optical Group at Rafael's system division and Development Engineer at Surface Technologies. Amit started a career in the Israel Defense Forces as a Professional Officer. Amit holds a Bachelor of Science in Mechanical Engineering from the Israel Institute of Technology, Technion, earned between 1990 and 1994.
This person is not in any offices
Notal Vision
Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending retinal disease monitoring from the clinic to the home, providing physicians with remote monitoring services to support their patient care between office visits. With a proven approach to home-based, self-operated diagnostics, AI-enabled data analysis, and patient engagement, we help preserve patients’ vision. The Notal Vision Monitoring Center is a remote, Medicare credentialed ophthalmic provider and the epicenter of patient engagement. Led by practicing ophthalmologists and supported by certified ophthalmic professionals, the Monitoring Center offers a comprehensive nationwide age-related macular degeneration (AMD) home monitoring service for referred patients. The ForeseeHome® AMD Monitoring Program helps physicians detect the conversion to wet AMD early, leading to earlier treatment intervention and better visual outcomes. Our Home OCT pipeline technology will provide patient-initiated retinal OCT scans to support the management of patients with neovascular retinal diseases, complementing existing in-office imaging and standard of care treatments as well as emerging longer acting drugs and drug delivery systems.